300878.SHE Wecome Pharmaceutical Co Ltd
- Market cap
- CNY 4.02B
- P/E
- -
- P/B
- 4.47x
- ROE
- -5.0%
- Dividend yield
- 0.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 300878.SHE undervalued?
Graham numberThe Graham number of Wecome Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wecome Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Wecome Pharmaceutical Co Ltd yet.
Wecome Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Lim…
Full company profileWecome Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wecome Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 282M | 407M | 578M | 642M | 623M | 633M | 532M | 520M | 351M | 225M | 252M |
| Gross Profit | 171M | 282M | 435M | 474M | 451M | 429M | 313M | 262M | 128M | 70.0M | 102M |
| Operating Income | 75.6M | 105M | 103M | 147M | 159M | 99.1M | 64.9M | -1.90M | -154M | -85.6M | -13.7M |
| EBITDA | 104M | 116M | 111M | 161M | 171M | 116M | 98.5M | 49.4M | -90.6M | -139M | -34.5M |
| Net Income | 80.9M | 95.2M | 87.8M | 126M | 136M | 96.5M | 48.8M | -8.95M | -147M | -227M | -44.5M |
| EPS | 0.74 | 0.88 | 0.81 | 1.16 | 1.13 | 0.67 | 0.34 | -0.06 | -1.03 | -1.57 | -0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 315M | 480M | 641M | 876M | 1.63B | 1.69B | 1.91B | 2.05B | 1.65B | 1.25B | 1.27B |
| Total Liabilities | 104M | 174M | 247M | 356M | 244M | 284M | 502M | 639M | 478M | 328M | 366M |
| Shareholders' Equity | 211M | 306M | 394M | 520M | 1.38B | 1.40B | 1.40B | 1.39B | 1.16B | 910M | 888M |
| Cash & Short-term Investments | 92.7M | 107M | 83.2M | 161M | 595M | 281M | 163M | 576M | 254M | 137M | 175M |
| Total Debt | - | 28.5M | 70.2M | 165M | 14.7M | 82.3M | 319M | 425M | 202M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 100M | 29.0M | 106M | 113M | 42.8M | -67.7M | 147M | 58.3M | -27.2M | 67.1M | - |
| Capital Expenditure | 48.0M | 42.0M | 173M | 115M | 152M | 171M | 248M | 139M | 127M | 67.2M | 18.0M |
| Free Cash Flow | 52.2M | -13.0M | -67.2M | -2.21M | -110M | -239M | -102M | -81.0M | -154M | -81.7K | -67.2M |
| Ratios | |||||||||||
| ROE | 38.3% | 31.1% | 22.3% | 24.2% | 9.8% | 6.9% | 3.5% | -0.6% | -12.7% | -25.0% | -5.0% |
| ROA | 25.7% | 19.8% | 13.7% | 14.4% | 8.3% | 5.7% | 2.6% | -0.4% | -8.9% | -18.2% | -3.5% |
| Net Profit Margin | 28.7% | 23.4% | 15.2% | 19.6% | 21.8% | 15.2% | 9.2% | -1.7% | -42.0% | -100.9% | -17.6% |
| Debt to Equity | - | 0.09x | 0.18x | 0.32x | 0.01x | 0.06x | 0.23x | 0.31x | 0.17x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wecome Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.71%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 28.4M | 0.20 | - |
| 2024 | CNY 44.4M | 0.31 | - |
| 2023 | CNY 7.02M | 0.05 | - |
| 2022 | CNY 43.4M | 0.30 | 89.0% |
| 2021 | CNY 80.4M | 0.56 | 83.4% |
| 2020 | CNY 7.83M | 0.07 | 5.8% |
| 2019 | CNY 5.73M | 0.05 | 4.5% |
| 2018 | CNY 1.42M | 0.01 | 1.6% |
| 2017 | CNY 17.7K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.8:1 on Jun 17, 2022.
Who owns Wecome Pharmaceutical Co Ltd
- Insiders 74.29%
- Institutions 0.01%
- Public & others 25.70%
- Shares outstanding 145M
- Free float 36.8M
Wecome Pharmaceutical Co Ltd company profile
- Company name
- Wecome Pharmaceutical Co Ltd
- Ticker
- 300878.SHE
- ISIN
- CNE1000047P9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 535
- Fiscal year end
- December
- Address
- No. 2, Suisong Road, Lishui, China, 323000
- Phone
- 86 57 8295 0088
- Website
- zjwk.com
About Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is headquartered in Lishui, China.
Wecome Pharmaceutical Co Ltd management
6- Mr. Yang LiuChairman & GM · born 1991
- Ms. Jing WangFinance Director & Accounting Supervisor · born 1987
- Ms. Xiaoxia KongDeputy General Manager · born 1982
- Mr. Jingwei DingDeputy General Manager · born 1974
- Ms. Dong LiuDeputy General Manager · born 1990
- Mr. Zhang Qi ZhangDeputy General Manager · born 1984